Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1826 in advanced solid tumors
NCT06094556Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Dec 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-1826 in solid tumor (advanced stage), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Dose-limiting toxicity at 21 Days, Maximum tolerated dose and 1 more. Started Dec 2023; status: recruiting.
02
Drugs
SHR-1826
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06094556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094556.